

# Research in the Department of Surgery at IUSOM Cryptic Masons Conference

Troy A. Markel, MD Associate Professor of Surgery Vice Chair for Research Department of Surgery Indiana University School of Medicine Indiana University Health



# Robust Research in Department

- Basic/Translational Sciences
  - Working with Space Allocation
     Committee to develop a common lab for the Surgical Sciences
  - Has the potential to be a "named lab"
- Surgical Education Research
- Health Services/SOQIC



Michael P. Murphy, MD

Cryptic Masons Medical Research Foundation

Professor of Vascular Biology Research



Associate Professor of Surgery

Al Hassanein, MMSC, MD



Meijing Wang, MD, MS

Associate Research Professor of Surgery



**Burcin Ekser, MD, PhD**Associate Professor of Surgery



**Linda M. Schutzman, MD**Assistant Professor of Surgery



**Gregory Borschel, MD**James Joseph Harbaugh, Jr. Professor of Plastic Surgery



Erin L. Weber, MD, PhD

Assistant Professor of Surgery



**Troy A. Markel, MD**Associate Professor of Surgery



C Max Schmidt, MD, PhD
Professor of Surgery



**Mithun Sinha, PhD**Assistant Professor of Surgery



Mark D. Rodefeld, MD

Professor of Surgery

### **Education Research**











- Skills Curriculum
- Simulation
- Providing Feedback
- Curriculum Design and Evaluation



- Health services
- Health care quality and safety
- Outcomes
- Health policy evaluation
- Quality and safety improvement
- Implementation science
- Surgical education research

Covers all surgical specialties (and areas of medicine)

### **SOQIC Faculty**



Karl Y. Bilimoria, MD, MS

Chair and Professor of Surgery SOOIC Executive Director



Andrew A. Gonzalez. MD

Assistant Professor of Surgery Associate Director



Anthony D. Yang, MD, MS

Professor of Surgery Associate Director



Rachel Patzer, PhD, MPH

Professor of Surgery President and CEO, Regenstrief Institute



Clint Cary, MD, MPH

Associate Professor of Urology Director of Urologic Oncology Research



Jeanette W. Chung, PhD, MA

Research Assistant Professor



Jill D. Connors, PhD, MSW, MS

Assistant Professor of Surgery



Kelsey M. Drewry, PhD, MA

Assistant Professor of Surgery



Joshua S. Eng, PhD

Research Assistant Professor of Surgery



Peter C. Jenkins, MD, MSC

Associate Professor of Surgery



Katelyn G. Makar, MD, MS

Assistant Professor of Surgery



Ashley D. Meagher, MD

Assistant Professor of Surgery



Sanjay Mohanty, MD

Assistant Professor of Surgery



Damaris Ortiz, MD

Assistant Professor of Surgery



Katherine Ross-Driscoll, PhD

Assistant Professor of Surgery



Dimitrios Stefanidis, MD, PhD

Professor of Surgery



Ryan Ellis, MD

Assistant Professor of Surgery



Tarik Yuce, MD

Assistant Professor of Surgery





David D. Odell, MD, MS

Adjunct Associate Professor of Surgery



Jane Holl, MPH, MD Adjunct Professor of Surgery




Yue-Yung Hu, MPH, MD Adjunct Assistant Professor of Surgery

## **Selected Current SOQIC Programs**

- National Surgical Education Numbered Trials Group
- Cancer Quality
- Health Policy
- Iliana Quality Collaboratives
- Using Video to Improve Technique
- Perioperative Patient and Surgical Safety
- Evaluating and Improving National Quality and Safety Ranking Systems
- Transplant Disparities
- Numerous others

## Blue Ridge NIH Ranking







From Inflammation to Immune Resilience: Chondroitin Sulfate's promising role in prevention of Necrotizing Enterocolitis

Troy Markel, MD Indiana University School of Medicine Department of Surgery Division of Pediatric Surgery

## **Necrotizing Enterocolitis**

- "Necrotizing enterocolitis is a devastating intrabdominal emergency of the newborn..."
- It often requires intestinal resection, and may leave infants with a less than desirable amount of small intestine
- The onset of this disease is incompletely understood



### **Trifecta**

- 1. Prematurity
- 2. Stress
  - High concentration formula feeds
  - Low oxygen levels
  - Infection
- 3. Incomplete Bacterial Gut Colonization




### **Incidence and Cost**

- 1. 7-10% of the 450,000 infants born prematurely each year are affected
- 2. 40-50% mortality
- 3. 19% of NICU expenditures-(\$5 billion a year in US alone)
  - Medical management adds \$73,000 + 22 hospital days
  - Surgical management adds \$260,000 and 60 hospital days
- 4. Breast milk is best method to prevent NEC
- 5. Probiotics also seem to be helpful, but no FDA approved formulas
- 6. NO SIGNIFICANT ADVANCEMENTS IN NEC TREATMENT IN LAST 30 YEARS!!!!



## **Potential Therapy: Chondroitin Sulfate**



#### Chondroitin Sulfate

GAG found in human milk


Decreased nuclear translocation of NFkB → ↓ proinflammatory cytokines

Benefits in autoimmune/osteoarthritis/IBD



Benefit in NEC?


#### **Concentration of Chondroitin Sulfate**




## Methods



AIM 1: In murine model of NEC, treatment with oral chondroitin sulfate in formula will improve clinical and biochemical outcomes in NEC




AIM 2: Necrotizing **Enterocolitis results** in downstream neurodevelopmental impairment. Administration of CS is neuroprotective



## Results




## **Oral Chondroitin Sulfate Improves NEC outcomes**





NEC NEC+ oral CS


↑Intestinal Injury ↓ Intestinal Injury




## **Oral Chondroitin Sulfate Improves NEC outcomes**












## Air-space/Alveolar area (Terminal Differentiation)



### **Lung Injury Score**




## **Oral Chondroitin Sulfate Improves NEC outcomes**



#### NEC NEC+ oral CS ↑Intestinal Injury **↑Lung Injury** ↓ Lung Injury ↓ Proinflammatory (IL-17A, ↑ Proinflammatory (IL-17A, TNFa, IL-6, IL-1B), AND ↑Anti-TNFa, IL-6, IL-1B), JAntiinflammatory inflammatory (IL-10) Cytokines in Cytokines(IL-10, IL-22) in intestine/lung intestines/lung

## Oral Chondroitin Sulfate Improves NEC outcomes



### NEC

↑Intestinal Injury

**↑Lung Injury** 

↑ Proinflammatory (IL-17A, TNFa, IL-6, IL-1B), ↓Antiinflammatory (IL-10) Cytokines in intestine/lung

↑ Microglial Activation, astrogliosis, and deleterious cortical changes


### **NEC+ oral CS**

↓ Intestinal Injury

↓ Lung Injury


Proinflammatory (IL-17A,
 TNFa, IL-6, IL-1B), AND ↑Anti inflammatory
 Cytokines(IL-10, IL-22) in
 intestines/lung

↓ Microglial Activation,
 ↓ astrogliosis, and improved
 cortical changes




NEC and intestinal injury results in microglial activation

Postnatal CS
therapy
attenuates
microglial
activation in
the brain



## Oral Chondroitin Sulfate Improves NEC outcomes



NEC

NEC+ oral CS

↑Intestinal Injury

↓ Intestinal Injury

↑Lung Injury

↓ Lung Injury

↑ Proinflammatory (IL-17A, TNFa, IL-6, IL-1B), ↓Antiinflammatory (IL-10) Cytokines in intestine/lung Proinflammatory (IL-17A,

TNFa, IL-6, IL-1B), AND ↑Antiinflammatory


Cytokines(IL-10, IL-22) in
intestines/lung

↑ Microglial Activation, astrogliosis, and deleterious cortical changes


↓ Microglial Activation,
 ↓ astrogliosis, and improved
 cortical changes

Delayed Developmental Milestones

Improved Developmental Milestones



NEC and intestinal injury results in delay in developmental milestones



Postnatal CS therapy prevents delay of developmental milestones

**Grip Strength** 


Degree mesh is

tilted until fall

## Conclusions



## Oral Chondroitin Sulfate Improves NEC outcomes



### NEC

↑Intestinal Injury

↑Lung Injury

↑ Proinflammatory (IL-17A, TNFa, IL-6, IL-1B), ↓Antiinflammatory (IL-10) Cytokines in intestine/lung

↑ Microglial Activation, astrogliosis, and deleterious cortical changes

Delayed Developmental Milestones

Altered Immune Profile

### **NEC+ oral CS**

↓ Intestinal Injury

↓ Lung Injury

→ Proinflammatory (IL-17A, TNFa, IL-6, IL-1B), AND ↑Antiinflammatory Cytokines(IL-10, IL-22) in intestines/lung

↓ Microglial Activation,
 ↓ astrogliosis, and improved
 cortical changes

Improved Developmental Milestones

Improved Immune Profile

## **Future Directions**







Partner with a milk fortifier company to add CS to further study differences in breast milk and donor milk and consider adding CS to their product





Begin steps for clinical trial to be able to add pharmaceutical grade CS to all formula products that neonates receive

# How can the Cryptic Masons Continue to Support Our Department

- 1. Grateful for Dr. Murphy's Chair position...
  - CM Young Investigator?
- 2. Naming rights and sponsorship of Department's Collective Lab
  - Vera Bradley Foundation Center for Breast Cancer Research
  - Brown Center for Immunotherapy
  - Krannert Cardiovascular Research Center
  - Herman B. Wells Center for Pediatric Research
- 3. High ticket equipment needs to maintain state of the art research at IU
  - Possible Development of a service core surrounding that equipment